Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Content from other channels on our network

Dairy drinks maker installed aseptic PET packaging line at greenfield facility

Robots that see around corners

Health Star Ratings set to become regulated in Australia and NZ

Fast detection of food contamination using enhanced AI tool

Abattoir safety program in WA raises more awareness

Gilmour Space opens office in South Australia

Myriota launches satellite global asset tracking

Cyber risk is rising faster than Australian manufacturers can respond

Fortescue commissions first battery electric locomotives

Electric actuation: a gamechanger for upstream processes

Why physical device security is becoming a patient privacy issue in health care

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

InterSystems Honoured with Four 2026 Best in KLAS Awards